PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
AstraZeneca and MedImmune: A Match Made in Biologics Heaven?
From issue 84 of the PharmaDeals Review (2007-06-01)
Biologics have rapidly established themselves as ‘the next big thing’, in the search for blockbuster wonder drugs, and everyone wants in, period. The relative sparseness of viable target companies has pushed the premiums to new highs, as the major global players compete to buy a future stake in the biologics arena. The latest addition to the list of companies to bow to shareholder pressure is MedImmune, which has agreed to be acquired by global giant AstraZeneca for US$15.6 B. This article explores the rationale behind the deal in order to provide an insight into why AstraZeneca was willing to go the extra mile for MedImmune.
Available as PDF
(Subscribers only)
Novartis In-licenses Cytos’ Smoking Vaccine
From issue 84 of the PharmaDeals Review (2007-06-01)
This feature discusses the recent US$497 M licensing deal between Cytos Biotechnology and Novartis for CYT002-NicQb, a therapeutic vaccine in Phase II clinical development for the treatment of nicotine addiction. Growing health awareness, combined with restrictions on smoking in an increasing number of countries worldwide, has boosted the market potential for anti-smoking products. CYT002-NicQb is competing with two other nicotine vaccines to be the first to be launched. This article puts the deal into the context of the current smoking cessation market and explores the strategy and rationale behind it.
Available as PDF
(Subscribers only)
How Companies Source their Licensing Opportunities, Part I: The Need to Partner Continues to Grow
From issue 84 of the PharmaDeals Review (2007-06-01)
As demonstrated by the size of the recent 2007 BIO International Convention, the biotechnology industry is continuing to grow in importance. As the pace of drug development within the biotechnology industry carries on accelerating, there is an increasing need to find partners with whom to develop and market these drugs. However, the process of finding suitable partners is still one which challenges companies of all sizes. To examine these challenges, PharmaVentures has conducted a survey of company executives involved in the sourcing of licensing opportunities. In this two-part article, we present the results of this survey. Here, in Part 1, we look at who is doing the sourcing of opportunities within companies, and discover that there is an across-the-board desire to optimise this process.
Available as PDF
(Subscribers only)
Therapy Focus: Anaemia in Chronic Kidney Disease and Cancer
From issue 84 of the PharmaDeals Review (2007-06-01)
Anaemia is a serious problem, not just for those with a lack of iron in their diet but for millions of patients with kidney disease, and for those undergoing cancer treatment. Anaemia in these cases results from the loss of a key protein called erythropoietin (EPO), which stimulates red blood cell production. The market is dominated by Amgen and Johnson & Johnson, whose sales of recombinant EPO replacement drugs (epoetins) totalled nearly US$10 B in 2006. However, threats are looming that may disrupt this dominance. Safety fears over the long-term use of epoetins, the impending introduction of biosimilars and the launch of newer and longer lasting treatments, such as Roche’s CERA, will provide the biggest shake up in the market’s 20-year history.
Available as PDF
(Subscribers only)
A Shot in the Arm for Oxford BioMedica
From issue 83 of the PharmaDeals Review (2007-05-01)
The remarkable expansion in our understanding of oncology and the processes by which cancer arises has provided the foundation on which to build a diverse range of therapeutic approaches that offer hope to future patients. One of these is TroVax®, a cancer vaccine that has been developed by Oxford BioMedica. In order to secure the future of the product, the company has signed potentially the largest ever deal for a cancer vaccine with the global pharmaceutical company sanofi-aventis. This article puts this deal into the context of the current oncology market and explores the strategy and rationale behind it.
- Journal Home
-
Help: Review Search
Combining search terms
Simply enter each search term (word), separated by a space to require all of these terms to be present in the search
E.G. cancer glaxo
Quoting phrases as search terms
If you wish to include a phrase as a search term, simply add quotation marks (" ") around the phrase
E.G. "drug delivery" "Type 1 diabetes"
Excluding search terms
To ensure that a specific search term is not in the search results, prefix the term with a "-" (though you must have at least one required search term)
E.G. drug -cancer -"drug delivery"
- Table of Content: Current Issue
- Commentaries
Last Issue PDF- Browse by Issue
- Browse by Section
- Conference Calendar
- Subscribe
- About
- Copyright Notice
- Contact Us
-
RSS Feed info
This feed will show the latest articles published in the current issue.
RSS